Self-Funded ERISA Plans: Subrogation Rights and Pharmacy Lien Strategy

James Wong — Founder & Pharmacist, LienScripts | March 26, 2026 | 7 min read

Self-funded ERISA plans hold the strongest subrogation rights in personal injury — state-law protections do not apply. PI attorneys need a defensive strategy that separates pharmacy costs from plan-paid expenses using a lien-based approach.

Self-funded ERISA plans possess the most aggressive subrogation rights in the personal injury landscape because federal preemption under 29 USC 1144 eliminates state-law protections that would otherwise limit or reduce the plan's recovery. A pharmacy lien strategy is the most effective defense against ERISA subrogation on medication costs because it keeps prescription expenses entirely outside the plan's payment system.

• Self-funded ERISA plans are exempt from state anti-subrogation statutes, made-whole doctrines, and collateral source rules
• Over 60% of employer-sponsored health coverage in the U.S. is self-funded, making ERISA subrogation a majority-case issue
• Pharmacy liens create a parallel payment channel that the ERISA plan cannot reach through subrogation
• The plan can only subrogate against costs it actually paid — lien-dispensed medications are categorically excluded
• LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report documenting all lien-funded medications separately from plan-paid expenses

Why Self-Funded Plans Have Superior Subrogation Rights

The distinction between fully insured and self-funded plans is the single most consequential coverage determination in PI cases. Fully insured plans — where the employer pays premiums to a commercial insurer like Aetna or Blue Cross — remain subject to state insurance regulation. Many states impose made-whole requirements, common fund obligations, or outright anti-subrogation rules on these plans.

Self-funded plans operate differently. The employer bears the financial risk directly, using a trust fund to pay claims, and hires a third-party administrator (TPA) to process them. Under ERISA's preemption clause, these plans are beyond the reach of state insurance regulation entirely.

The Supreme Court established this framework in FMC Corp. v. Holliday, 498 U.S. 52 (1990), and reinforced it in Sereboff v. Mid Atlantic Medical Services, 547 U.S. 356 (2006), which confirmed that ERISA plans can enforce equitable liens against specifically identifiable settlement funds under Section 502(a)(3), 29 U.S.C. § 1132(a)(3).

[!KEY] When a PI client's employer health plan is self-funded, the plan's SPD language controls subrogation — not state law. If the SPD says "first dollar recovery" with no offset for attorney fees, the plan can enforce that term unless the attorney successfully invokes McCutchen or Montanile.

Identifying Self-Funded Plans at Intake

Every PI intake should include a coverage determination. Self-funded status appears in several places:

Summary Plan Description (SPD). Look for language stating "This plan is self-funded by [Employer]" or "The employer assumes financial responsibility for claims." The SPD also identifies the TPA.

Insurance card clues. If the card shows a major insurer name (e.g., UnitedHealthcare) but the employer is a large company with 500+ employees, the insurer may be acting as TPA only. Confirm with the SPD.

Plan document. The formal plan document (distinct from the SPD) contains the definitive funding arrangement. Request it through the TPA or employer's HR department.

According to Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist, "We flag ERISA-governed cases during enrollment so that our pharmacy team and the attorney's office are aligned on documentation strategy from day one. The MERIT report for ERISA cases specifically delineates which medications were lien-funded versus plan-paid, which simplifies settlement allocation."

The Defensive Strategy: Pharmacy Liens as ERISA Shields

The core defensive principle is straightforward: an ERISA plan can only subrogate against costs it paid. If the plan never paid for the client's prescription medications, it has no subrogation interest in those costs — regardless of how broadly the SPD's subrogation clause is drafted.

Step 1: Enroll in a pharmacy lien at intake. Before any prescriptions are billed to the employer's health plan, establish a pharmacy lien arrangement. All injury-related medications are dispensed through the lien provider at zero upfront cost to the patient.

Step 2: Ensure no pharmacy claims reach the plan. The lien provider fills prescriptions without billing the employer plan. No EOBs are generated for pharmacy claims. The plan's records show zero medication expenditure for the injury.

Step 3: Document the separation. At settlement, the MERIT report from LienScripts provides a complete medication history showing every prescription was lien-funded. When the TPA's subrogation demand arrives, respond with documentation proving the plan paid nothing for medications.

[!TIP] If your client has already filled some prescriptions through their employer plan before intake, identify which medications were plan-paid versus lien-funded. The plan can legitimately subrogate on the plan-paid fills, but not on lien-funded medications dispensed after enrollment.

Responding to TPA Subrogation Demands

TPAs administering self-funded plans issue subrogation demands that are often overbroad. A typical demand letter asserts recovery rights over "all medical expenses related to the injury, including pharmacy costs." The key responses:

Request itemized accounting. Demand that the TPA provide every EOB, remittance, and payment record for the client. This reveals exactly what the plan paid. If pharmacy costs are listed, verify whether those are pre-lien fills or errors.

Challenge estimated pharmacy figures. TPAs sometimes include estimated medication costs without verifying whether the plan actually processed those claims. Counter with the MERIT report showing that all post-enrollment medications were lien-funded.

Assert McCutchen common fund. If the SPD is silent on attorney fees, invoke US Airways v. McCutchen, 569 U.S. 88 (2013), to reduce the plan's net recovery by requiring pro-rata contribution to the contingency fee.

Preserve Montanile arguments. Under Montanile v. Board of Trustees, 577 U.S. 136 (2016), the plan's equitable lien attaches only to specifically traceable settlement funds. Strategic disbursement timing — with proper notice to the TPA — can limit the plan's enforcement options.

Settlement Waterfall with Self-Funded ERISA Claims

When both an ERISA subrogation claim and a pharmacy lien exist, the settlement waterfall looks like this:

1. Gross settlement received into trust account
2. Attorney fees and costs deducted per retainer agreement
3. ERISA plan recovery — limited to amounts actually paid, reduced by McCutchen common fund if applicable
4. Pharmacy lien — satisfied from net proceeds for lien-funded medication costs
5. Client net recovery — remaining funds disbursed to client

The pharmacy lien and the ERISA subrogation claim do not compete for the same dollars because they cover different expenses. The plan recovers what it paid for (imaging, procedures, pre-lien medications). The pharmacy lien recovers what the lien provider advanced (post-enrollment prescriptions). Clean documentation prevents overlap disputes.

[!KEY] Self-funded ERISA plans are formidable adversaries at settlement, but their subrogation power has a clear boundary: they can only recover costs they actually incurred. A pharmacy lien strategy exploits this boundary by ensuring medication costs never enter the plan's system in the first place.

Related Resources

• ERISA Preemption and Pharmacy Liens: Attorney Guide
• ERISA Made-Whole Doctrine and Pharmacy Liens
• ERISA Common Fund Doctrine and Pharmacy Recovery
• Pharmacy Lien vs. ERISA Health Plan: What PI Attorneys Need to Know